The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
AimPharmacogenetic studies have identified the presence of the HLA‐A*31:01 allele as a predictor of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services.
MethodsAttributes of importance to people with epilepsy and neurologists were identified through interviews and...
ObjectiveCarbamazepine causes severe cutaneous adverse drug reactions that may be predicted by the presence of the HLA‐A*31:01 allele in northern European populations. There is uncertainty as to whether routine testing of patients with epilepsy is cost‐effective. We conducted an economic evaluation of HLA‐A*31:01 testing from the perspective of the National Health Service (NHS) in the United Kingdom...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.